Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
Cancer Vaccines01:30

Cancer Vaccines

Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Datopotamab deruxtecan (Dato-DXd) in combination with durvalumab as first-line treatment for unresectable locally advanced or metastatic triple-negative breast cancer: results from arms 7 and 8 of the phase Ib/II BEGONIA study.

Annals of oncology : official journal of the European Society for Medical Oncology·2026
Same author

Renal carcinoma CD105-/CD44- cells display stem-like properties in vitro and form aggressive tumors in vivo.

Scientific reports·2020
Same author

Prognostic impact of baseline tumour immune infiltrate on disease-free survival in patients with completely resected, BRAF<sup>v600</sup> mutation-positive melanoma receiving adjuvant vemurafenib.

Annals of oncology : official journal of the European Society for Medical Oncology·2020
Same author

HCV viraemia associates with NK cell activation and dysfunction in antiretroviral therapy-treated HIV/HCV-co-infected subjects.

Journal of viral hepatitis·2017
Same author

Comparative studies of cervical spine anterior stabilization systems--Finite element analysis.

Clinical biomechanics (Bristol, Avon)·2016
Same author

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe.

Expert opinion on pharmacotherapy·2015

Related Experiment Video

Updated: Jul 15, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Recent developments in renal cell cancer immunotherapy.

P J Wysocki1, J Zolnierek, C Szczylik

  • 1Chair of Medical Biotechnology, University of Medical Sciences at GreatPoland Cancer Center, Department of Cancer Immunology, ul. Garbary 15, 61-866 Poznan, Poland. pwysocki@plusnet.pl

Expert Opinion on Biological Therapy
|May 5, 2007
PubMed
Summary

Immunotherapy for renal cell carcinoma (RCC) shows promise for potential cures, despite moderate efficacy in advanced stages. Recent advancements focus on specific patient selection and optimized response criteria for future clinical trials.

More Related Videos

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Related Experiment Videos

Last Updated: Jul 15, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
06:38

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies

Published on: April 12, 2017

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy
11:27

Modeling Spontaneous Metastatic Renal Cell Carcinoma (mRCC) in Mice Following Nephrectomy

Published on: April 29, 2014

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells
11:08

Advances in Human Induced Pluripotent Stem Cell-Derived Chimeric Antigen Receptor-Expressing Natural Killer Cells

Published on: February 14, 2025

Area of Science:

  • Oncology
  • Immunology

Background:

  • Renal cell carcinoma (RCC) treatment has explored immunotherapy for over 90 years.
  • Current immunotherapies include cytokines, vaccines, monoclonal antibodies, and adoptive T cell transfer.
  • Despite advancements, immunotherapy's efficacy for advanced RCC remains moderate.

Purpose of the Study:

  • To review recent progress in immunotherapeutic approaches for renal cell carcinoma.
  • To highlight the potential of immunotherapy as a curative systemic strategy for RCC.
  • To discuss future directions and necessary optimizations for clinical trials.

Main Methods:

  • Review of existing immunotherapeutic strategies for RCC.
  • Analysis of recent advancements in active and passive specific immunotherapy.
  • Discussion of methods to overcome immunosuppressive mechanisms.

Main Results:

  • Significant progress has been made in immunotherapeutic approaches for RCC in the last two years.
  • Targeted therapies have shown significant efficacy in metastatic RCC, shifting focus from traditional immunotherapy.
  • Immunotherapy remains the only approach with the potential for a cure in RCC patients.

Conclusions:

  • New immunotherapeutic strategies, including targeting immunosuppressive mechanisms, are emerging.
  • Future trials require optimally selected patients and specialized tumor response criteria.
  • Immunotherapy holds potential for curative treatment in RCC, necessitating refined clinical trial designs.